Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
- Uncovering preclinical evidence to showcase the potential for NRAS and HRAS-targeting programs
- How to selectively target NRAS or HRAS and minimize off-target effects
- How to develop a successful patient stratification strategy for clinical trials related to NRASmutant and HRAS-mutant cancer